Items Tagged ‘Head and Neck Cancer’

August 21st, 2017

U.S. FDA Removes Clinical Hold on CEL-SCI’s Phase 3 Head & Neck Cancer Trial

By

CEL-SCI Corporation today announced it has received a letter from the U.S. Food and Drug Administration (FDA) stating that the clinical hold that had been imposed on the Company’s Phase 3 cancer study with Multikine* (Leukocyte Interleukin, Inj.) has been removed and that all clinical trial activities under this Investigational New Drug application may resume. […]

View full entry

Tags: Head and Neck Cancer, immunotherapy, interleukin, Leukocyte, Multikine, News


August 14th, 2017

Head and Neck Cancer-What You Need to Know

By

Head and neck cancer includes a number of different malignant cancers that develop in or around the throat, larynx (voice box), nose, sinuses and mouth. Globally, head and neck cancer is the seventh most common type of cancer with an estimated 400,000-600,000 diagnoses every year. Head and neck cancers account for about 3 percent of […]

View full entry

Tags: checkpoint inhibitors, Head and Neck Cancer, human papilloma virus, keytruda, News, opdivo, PD-1, Throat Cancer


February 22nd, 2017

Targeted radiotherapy for head and neck cancer could reduce the risk of dry mouth

By

A troublesome side effect of radiation therapy treatment of cancers involving the head and neck is dry mouth.  This occurs as a consequence of radiation damage to the salivary glands.  According to a new study, changing the intensity of radiotherapy to protect the salivary glands could help treat a rare type of head and neck […]

View full entry

Tags: Head and Neck Cancer, News, radiation


February 20th, 2017

Nearly half of U.S. men actively infected with HPV, study finds HPV-linked cancers on the rise in men, but nearly 9 in 10 vaccine-eligible men are unvaccinated!

By

By Rachel Tompa / Fred Hutch News Service The most common sexually transmitted infection in the U.S. has a bit of a twist. It’s what’s known as a “subclinical infection” — those infected suffer no immediate consequences, but years later have vastly increased risks for at least six different types of cancer. That sleeper agent […]

View full entry

Tags: Cervical Cancer, Head and Neck Cancer, hpv, News, oropharyngeal cancer, vaccine


February 14th, 2017

Twice-daily radiation therapy reduces mortality from head and neck cancer

By

Treating head and neck cancer patients with a twice-daily radiation therapy schedule combined with chemotherapy could save more lives, according to new research presented at the European Cancer Congress 2017.1 Around 600,000 people are diagnosed with head and neck cancer worldwide each year. It can be difficult to treat because the area of the body […]

View full entry

Tags: General Head and Neck Cancer, Head and Neck Cancer, News


November 28th, 2016

Opdivo Approved for Advanced Head and Neck Cancer

By

The United States Food and Drug Administration (FDA) has approved the immunotherapeutic agent, Opdivo® (nivolumab) for the treatment of advanced head and neck cancer. Specifically,  the indication is for the treatment of squamous cell carcinoma of the head and neck cancer (SCCHN) that has spread to distant sites in the body and has progressed or […]

View full entry

Tags: fda, General Head and Neck Cancer, Head and Neck Cancer, News, nivolumab, opdivo, schhn


October 5th, 2016

PET/CT Combined More Effective Than MRI in Monitoring Head and Neck Cancer Patients’ Response to Treatment

By

According to a recent study, combining PET/CT to monitor response to treatment in head and neck cancer patients appears more effective than MRI. Using PET/CT may better inform doctors whether treatment for head and neck cancer is working after just one cycle of chemotherapy. The ability to identify a patients response to chemotherapy early is […]

View full entry

Tags: General Head and Neck Cancer, Head and Neck Cancer, INSIGHT trial, MRI, News, PET/CT, squamous cell carcinoma


September 7th, 2016

Keytruda® Approved for Advanced Head and Neck Cancer

By

The United States Food and Drug Administration (FDA) has approved Keytruda® (pembrolizumab) for the treatment of advanced head and neck cancer that has stopped responding to platinum-based chemotherapy agents.1 Globally, head and neck cancer comprises the seventh most common type of cancer with an estimated 400,000-600,000 diagnoses every year. Head and neck squamous cell cancer […]

View full entry

Tags: advanced, fda, General Head and Neck Cancer, Head and Neck Cancer, keytruda, metastatic, News, pembrolizumab


June 9th, 2016

Compliance with Radiation Schedules Improves Survival in Head and Neck Cancer

By

Patients with head and neck cancer who comply with their scheduled radiation treatments have significantly improved outcomes compared to those who miss 2 or more of their appointments within the prescribed time period. These results were recently published in the International Journal of Radiation Oncology, Biology, Physics. Head and neck cancer refers to several different […]

View full entry

Tags: appointments, General Head and Neck Cancer, Head and Neck Cancer, HNC, News, radiation, schedule


June 8th, 2016

Long-Lasting Responses Achieved with Keytruda® in Advanced Head and Neck Cancer

By

Treatment with the immune-stimulating agent, Keytruda® (pembrolizumab), provides impressive long-term outcomes for some patients with metastatic or recurrent head and neck cancer. These results were recently presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). Globally, head and neck cancer comprises the seventh most common type of cancer with an […]

View full entry

Tags: advanced, ASCO 2016, General Head and Neck Cancer, Head and Neck Cancer, HNSCC, KEYNOTE-012, keytruda, metastatic, News, perbrolizumab, squamous cell cancer


June 6th, 2016

Follow-Up Scans Reduce Need for Some Invasive Surgeries in Head and Neck Cancer

By

Utilizing PET-CT scans following treatment for patients with head and neck cancer that has spread to their lymph nodes significantly reduces the need for invasive follow-up surgery. These results were recently published in the New England Journal of Medicine. Patients diagnosed with head and neck cancer (HNC) that has spread to nearby lymph nodes are […]

View full entry

Tags: chemoradiation, General Head and Neck Cancer, Head and Neck Cancer, HNC, lymph nodes, News, PET-CT scans, surgery


May 25th, 2016

More Evidence that PD-1 Inhibitors Improve Survival in Head and Neck Cancer

By

Results from a recent large trial indicate that treatment with the immunotherapy agent Opdivo® (nivolumab) nearly doubles the survival rate at one year in patients with advanced head and neck squamous cell carcinoma. These results prompted the United States Food and Drug Administration to grant Opdivo “breakthrough therapy designation” for the treatment of patients with […]

View full entry

Tags: Breakthrough Therapy Designation, CheckMate 141 clinical trial, fda, General Head and Neck Cancer, Head and Neck Cancer, News, nivolumab, opdivo, squamous cell


June 30th, 2015

Better Outcomes in Oral Cancer with Surgery to Remove Lymph Nodes in Neck before Cancer Spreads

By

In early squamous-cell oral cancer, surgery to remove lymph nodes in the neck before cancer spreads may result in better outcomes. These findings were presented at 2015 Annual Meeting of the American Society of Clinical Oncology (May 29–June 2, Chicago, Illinois) and published in the New England Journal of Medicine. Oral cancer refers to cancer […]

View full entry

Tags: General Head and Neck Cancer, Head and Neck Cancer, lymph nodes, neck dissection, News, oral cancer, squamous cell


June 8th, 2015

Keytruda® Promising in Advanced Head and Neck Cancer

By

The immunotherapy Keytruda® (pembrolizumab) appears active in the treatment of advanced squamous cell head and neck cancer. These findings were presented at 2015 Annual Meeting of the American Society of Clinical Oncology (May 29–June 2, Chicago, Illinois) and published in the Journal of Clinical Oncology.[i] Head and neck cancers originate in the tissues in or […]

View full entry

Tags: Head and Neck Cancer, keytruda, News, pembrolizumab


April 2nd, 2015

Medical and dental centers throughout U.S. will take part in 18th annual OHANCAW®, April 12-18

By

NEW YORK, NY, march 24, 2015 – Donnie Walsh, former President of the Indiana Pacers and New York Knicks and an oral cancer survivor, is urging Americans to get screened for cancer during the 18th annual Oral, Head & Neck Cancer Awareness Week® (OHANCAW®), being held nationwide April 12-18. More than 200 sites throughout the […]

View full entry

Tags: awareness week, General Head and Neck Cancer, Head and Neck Cancer, News, OHANCAW, OHNC